2. Academic Validation
  3. Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer

Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer

  • Antibodies (Basel). 2020 Oct 6;9(4):51. doi: 10.3390/antib9040051.
Ellinor I Peerschke 1,  Elisa de Stanchina 2,  Qing Chang 2,  Katia Manova-Todorova 2,  Afsar Barlas 2,  Anne G Savitt 3,  Brian V Geisbrecht 4,  Berhane Ghebrehiwet 5
Affiliations

Affiliations

  • 1 Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • 2 Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • 3 Department of Microbiology and Immunology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
  • 4 Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS 66506, USA.
  • 5 Departments of Medicine and Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
PMID: 33036212 DOI: 10.3390/antib9040051
Abstract

gC1qR is highly expressed in breast Cancer and plays a role in Cancer cell proliferation. This study explored therapy with gC1qR monoclonal antibody 60.11, directed against the C1q binding domain of gC1qR, in a murine orthotopic xenotransplant model of triple negative breast Cancer. MDA231 breast Cancer cells were injected into the mammary fat pad of athymic nu/nu female mice. Mice were segregated into three groups (n = 5, each) and treated with the vehicle (group 1) or gC1qR antibody 60.11 (100 mg/kg) twice weekly, starting at day 3 post-implantation (group 2) or when the tumor volume reached 100 mm3 (group 3). At study termination (d = 35), the average tumor volume in the control group measured 895 ± 143 mm3, compared to 401 ± 48 mm3 and 701 ± 100 mm3 in groups 2 and 3, respectively (p < 0.05). Immunohistochemical staining of excised tumors revealed increased Apoptosis (Caspase 3 and TUNEL staining) in 60.11-treated mice compared to controls, and decreased angiogenesis (CD31 staining). Slightly decreased white blood cell counts were noted in 60.11-treated mice. Otherwise, no overt toxicities were observed. These data are the first to demonstrate an in vivo anti-tumor effect of 60.11 therapy in a mouse model of triple negative breast Cancer.

Keywords

breast cancer; gC1qR; xenotransplant model.

Figures
Products